Abstract
Pulmonary vascular reactivity tests were performed in a young woman with mixed connective tissue disease and severe pulmonary hypertension. Vasoreactivity was documented in response to intravenous prostacyclin (PGI2), oral nifedipine, and inhaled nitric oxide, with quantitative differences. Nitric oxide produced a moderate lowering of pulmonary arterial pressure and resistance without any deleterious systemic effect. The use of nitric oxide in testing for pulmonary vasoreactivity merits further evaluation.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dahl M., Chalmers A., Wade J., Calverley D., Munt B. Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. J Rheumatol. 1992 Nov;19(11):1807–1809. [PubMed] [Google Scholar]
- Fiorentini C., Barbier P., Galli C., Loaldi A., Tamborini G., Tosi E., Guazzi M. D. Pulmonary vascular overreactivity in systemic hypertension. A pathophysiological link between the greater and the lesser circulation. Hypertension. 1985 Nov-Dec;7(6 Pt 1):995–1002. doi: 10.1161/01.hyp.7.6.995. [DOI] [PubMed] [Google Scholar]
- Fiorentini C., Barbier P., Galli C., Loaldi A., Tamborini G., Tosi E., Guazzi M. D. Pulmonary vascular overreactivity in systemic hypertension. A pathophysiological link between the greater and the lesser circulation. Hypertension. 1985 Nov-Dec;7(6 Pt 1):995–1002. doi: 10.1161/01.hyp.7.6.995. [DOI] [PubMed] [Google Scholar]
- Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109–142. [PubMed] [Google Scholar]
- Partanen J., Nieminen M. S., Luomanmäki K. Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine. N Engl J Med. 1993 Sep 9;329(11):812–813. doi: 10.1056/NEJM199309093291117. [DOI] [PubMed] [Google Scholar]
- Rich S., Kaufmann E., Levy P. S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992 Jul 9;327(2):76–81. doi: 10.1056/NEJM199207093270203. [DOI] [PubMed] [Google Scholar]